83463-12-1

Upstream product

• 3044-71-1 2,6-dimethyl-4-phenylpyridine 
• 162102-79-6 dimethyl 4-bromo-2,6-pyridinedicarboxylate 
• 19872-91-4 dimethyl 4-hydroxypyridine-2,6-dicarboxylate 
• 499-51-4 Chelidamic acid 
• 117095-82-6 4-phenyl-2,6-pyridinedicarboxylic acid diethyl ester 
• 5689-65-6 2,6-di(furan-2-yl)-4-phenylpyridine 
• 7732-18-5 water 
• 3988-74-7 (E)-1-(furan-2-yl)-3-phenylprop-2-en-1-one 
• 80927-46-4 1,5-Bis(2-furyl)-3-phenylpentan-1,5-dion 
• 138-60-3 chelidamic acid 
• 5371-70-0 dimethyl 4-chloro-2,6-pyridinedicarboxylate 
• 71022-75-8 4-chloropyridine-2,6-dicarbonyl dichloride 
• 117095-81-5 4-phenyl-2,6-pyridinedicarboxylic acid dimethyl ester 

Downstream Products

• 106023-86-3 C₁₃H₇Cl₂NO₂ 
• 117095-88-2 4-phenyl-2,6-pyrido-27-crown-9 
• 117095-84-8 4-phenyl-bis(2,6-bromomethyl)pyridine 
• 117095-83-7 2,6-bis(hydroxymethyl)-4-phenylpyridine 
• 939-23-1 p-phenylpyridine 
• 117095-81-5 4-phenyl-2,6-pyridinedicarboxylic acid dimethyl ester 

Relevant academic research and scientific papers

Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1

The efficacy of β-lactam antibiotics is threatened by the emergence and global spread of metallo-β-lactamase (MBL) mediated resistance, specifically New Delhi metallo-β-lactamase-1 (NDM-1). By utilization of fragment-based drug discovery (FBDD), a new class of inhibitors for NDM-1 and two related β-lactamases, IMP-1 and VIM-2, was identified. On the basis of 2,6-dipicolinic acid (DPA), several libraries were synthesized for structure-activity relationship (SAR) analysis. Inhibitor 36 (IC50 = 80 nM) was identified to be highly selective for MBLs when compared to other Zn(II) metalloenzymes. While DPA displayed a propensity to chelate metal ions from NDM-1, 36 formed a stable NDM-1:Zn(II):inhibitor ternary complex, as demonstrated by 1H NMR, electron paramagnetic resonance (EPR) spectroscopy, equilibrium dialysis, intrinsic tryptophan fluorescence emission, and UV-vis spectroscopy. When coadministered with 36 (at concentrations nontoxic to mammalian cells), the minimum inhibitory concentrations (MICs) of imipenem against clinical isolates of Eschericia coli and Klebsiella pneumoniae harboring NDM-1 were reduced to susceptible levels.

Rhodium-catalyzed asymmetric hydrosilylation of ketones employing a new ligand embodying the bis(oxazolinyl)pyridine moiety

A general approach to new ligands embodying bis(oxazolinyl)pyridine has been developed, employing palladium-catalyzed Suzuki coupling and base-mediated cyclization as pivotal steps. A rhodium catalyst derived from the ligand 4-(4-ethylphenyl)-2,6-bis(4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine gave excellent enantioselectivity in the asymmetric hydrosilylation of ketones. In addition the electronic effect of remote substituents on the catalytic activity of rhodium catalyst was studied.

Ruthenium-catalyzed asymmetric epoxidation of olefins using H 2O2, part I: Synthesis of new chiral N,N,N,-tridentate pybox and pyboxazine ligands and their ruthenium complexes

The synthesis of chiral tridentate N,N,N-pyridine-2.6-bisoxazolines 3 (pyhox ligands) and N,N,N-pyridine-2.6-bisoxazines 4 (pyboxazine ligands) is described in detail. These novel ligands constitute a useful tool-box for the application in asymmetric catalysis. Compounds 3 and 4 are conveniently prepared by cyclization of enantiomerically pure α- or β-amino al cohols with dimethyl pyridine-2,6-dicarboximidate. The corresponding ruthenium complexes are efficient asymmetric epoxidation catalysts and have been prepared in good yield and fully char acterized by spectroscopic means. Four of these ruthenium complexes have been characterized by X-ray crystallography. For the first time the molecular structure of a pyboxazine complex (2,6-bis-[(4S)-4-phenyl-5,6- dihydro-4H-[1,3]oxazinyl]pyridine)(pyridine-2,6-dicarboxylate)ruthenium (S)-2aa, is presented.

Substituted pyridine derivatives

It is disclosed that aryl-substituted 2,6-bis[N,N-di(carboxyalkyl)aminoalkyl] pyridines in which the aryl groups are substituted with one or more electron-releasing groups are an advantageous ligand for forming fluorescent chelates with rare earth metals. The pyridine moieties can be linked to target molecules, especially biologically active target molecules to provide fluorescent tagging for use in fluoroassay techniques. The pyridine moieties are disclosed as tetraacids, as salts and as esters. Preparation processes and precursors including the corresponding aryl-substituted 2,6-dicarboxypyridines as acids, salts and esters, are disclosed as well.